Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Operating Leases (2022 - 2025)

Historic Operating Leases for Dianthus Therapeutics (DNTH) over the last 4 years, with Q3 2025 value amounting to $1.1 million.

  • Dianthus Therapeutics' Operating Leases changed N/A to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year change of. This contributed to the annual value of $1.2 million for FY2024, which is 59702.38% up from last year.
  • Dianthus Therapeutics' Operating Leases amounted to $1.1 million in Q3 2025.
  • Over the past 5 years, Dianthus Therapeutics' Operating Leases peaked at $32.4 million during Q1 2022, and registered a low of $30000.0 during Q2 2024.
  • For the 4-year period, Dianthus Therapeutics' Operating Leases averaged around $8.1 million, with its median value being $1.1 million (2025).
  • Per our database at Business Quant, Dianthus Therapeutics' Operating Leases tumbled by 9905.43% in 2023 and then soared by 363000.0% in 2025.
  • Dianthus Therapeutics' Operating Leases (Quarter) stood at $438000.0 in 2022, then tumbled by 61.64% to $168000.0 in 2023, then surged by 597.02% to $1.2 million in 2024, then dropped by 8.8% to $1.1 million in 2025.
  • Its Operating Leases stands at $1.1 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.2 million for Q1 2025.